NeuShen Therapeutics, a Shanghai, China and Boston, MA-based biotechnology company focusing on developing treatments for central nervous system (CNS) disorders, raised approx. $20M in Pre-Series A funding.
The round was led by Lapam Capital.
The company intends to use the funds to expand the team and catalyze in-house CNS drug discovery in both the US and China.
Led by CEO Dr. Joan Shen, NeuShen Therapeutics is a biotechnology company focusing on innovative drug research and development to address CNS disorders, applying dual research platforms, including AAV-based gene therapy and small molecule discovery.
FinSMEs
03/10/2022